MacroGenics (NASDAQ:MGNX - Get Free Report) is anticipated to release its earnings data after the market closes on Thursday, March 20th. Analysts expect MacroGenics to post earnings of ($0.23) per share and revenue of $34.17 million for the quarter. Investors that wish to register for the company's conference call can do so using this link.
MacroGenics Stock Up 3.9 %
MGNX opened at $2.38 on Thursday. MacroGenics has a fifty-two week low of $2.15 and a fifty-two week high of $19.54. The firm has a market cap of $149.38 million, a PE ratio of -1.51 and a beta of 2.12. The business has a fifty day simple moving average of $2.83 and a 200-day simple moving average of $3.28.
About MacroGenics
(
Get Free Report)
MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MacroGenics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MacroGenics wasn't on the list.
While MacroGenics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
